Brucellosis vaccines: past, present and future

Schurig, Gerhardt G.; Sriranganathan, Nammalwar; Corbel, Michael J.

doi:10.1016/s0378-1135(02)00255-9

Cited by 346 publications

(319 citation statements)

References 73 publications

Supporting

Mentioning

288

Contrasting

Unclassified

Order By: Relevance

“…Under these conditions, the risk of disease spread from elk to elk and from elk to man (through skin wounds or by accidentally ingesting the bacteria after cleaning elk) is increased [60]. It is also worthy to note that to date, there is no vaccine that has proven to be safe and to provide a significative degree of protection in elk and bison, as well as in other wildlife species [39,54,65].…”

Section: Wildlifementioning

confidence: 99%

From the discovery of the Malta fever?s agent to the discovery of a marine mammal reservoir, brucellosis has continuously been a re-emerging zoonosis

et al. 2005

View full text Add to dashboard Cite

-Brucellosis is not a sustainable disease in humans. The source of human infection always resides in domestic or wild animal reservoirs. The routes of infection are multiple: foodborne, occupational or recreational, linked to travel and even to bioterrorism. New Brucella strains or species may emerge and existing Brucella species adapt to changing social, cultural, travel and agricultural environment. Brucella melitensis is the most important zoonotic agent, followed by Brucella abortus and Brucella suis. This correlates with the fact that worldwide, the control of bovine brucellosis (due to B. abortus) has been achieved to a greater extent than the control of sheep and goat brucellosis (due to B. melitensis), these latter species being the most important domestic animals in many developing countries. The long duration and high cost of treatment of human brucellosis reduces the efficacy of the therapy. There is no human vaccine for brucellosis and the occurrence of brucellosis is directly linked to the status of animal brucellosis in a region. In this context, the Word Health Organization has defined the development of a human vaccine, besides the implementation of control and eradication programs in animals, as a high priority. The pathogenicity for humans of B. suis biovars 1, 3 and 4 is well established, whereas B. suis biovar 2 seems to be less pathogenic. Indeed, although hunters and pig farmers have repeatably experienced infectious contact with B. suis biovar 2 (found in wild boar and outdoor-rearing pigs in Europe), isolation of B. suis biovar 2 from human samples have only been seldom reported. Marine mammal brucellosis, due to two new proposed Brucella species i.e. B. cetaceae and B. pinnipediae, represents a new zoonotic threat but the pathogenicity for humans of the different Brucella species found in cetaceans and pinnipeds still has to be clearly established.Brucella / animal and human brucellosis / zoonoses / domestic and wildlife reservoir

show abstract

Section: Wildlifementioning

confidence: 99%

From the discovery of the Malta fever?s agent to the discovery of a marine mammal reservoir, brucellosis has continuously been a re-emerging zoonosis

et al. 2005

View full text Add to dashboard Cite

show abstract

“…In addition to the implementation of a 'test-and-slaughter' strategy, vaccination is a critical tool for control of bovine brucellosis (Avila-Calderó n et al, 2013). In the last few decades, live-attenuated vaccines such as B. abortus strains S19 and RB51 have been developed and widely used against bovine brucellosis (Avila-Calderó n et al, 2013;Schurig et al, 2002). The strain RB51 vaccine was first reported in 1991 as a spontaneous mutant of B. abortus strain 2308 that developed an attenuated phenotype after repeated in vitro passage in the presence of rifampicin (Schurig et al, 2002).…”

Section: Introductionmentioning

confidence: 99%

“…In the last few decades, live-attenuated vaccines such as B. abortus strains S19 and RB51 have been developed and widely used against bovine brucellosis (Avila-Calderó n et al, 2013;Schurig et al, 2002). The strain RB51 vaccine was first reported in 1991 as a spontaneous mutant of B. abortus strain 2308 that developed an attenuated phenotype after repeated in vitro passage in the presence of rifampicin (Schurig et al, 2002). Numerous efficacy studies of this vaccine conducted in experimental mice and in cattle have demonstrated that the vaccinated animals, particularly cattle, are effectively protected from exposure to WT bacteria (Schurig et al, 2002;.…”

Section: Introductionmentioning

confidence: 99%

“…The strain RB51 vaccine was first reported in 1991 as a spontaneous mutant of B. abortus strain 2308 that developed an attenuated phenotype after repeated in vitro passage in the presence of rifampicin (Schurig et al, 2002). Numerous efficacy studies of this vaccine conducted in experimental mice and in cattle have demonstrated that the vaccinated animals, particularly cattle, are effectively protected from exposure to WT bacteria (Schurig et al, 2002;. The protective efficacy of RB51 is variable and depends on a range of factors, including the age of the vaccinated animal and the dose and route of the vaccination.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Booster vaccination with safe, modified, live-attenuated mutants of Brucella abortus strain RB51 vaccine confers protective immunity against virulent strains of B. abortus and Brucella canis in BALB/c mice

et al. 2015

View full text Add to dashboard Cite

Brucella abortus attenuated strain RB51 vaccine (RB51) is widely used in prevention of bovine brucellosis. Although vaccination with this strain has been shown to be effective in conferring protection against bovine brucellosis, RB51 has several drawbacks, including residual virulence for animals and humans. Therefore, a safe and efficacious vaccine is needed to overcome these disadvantages. In this study, we constructed several gene deletion mutants (DcydC, DcydD and DpurD single mutants, and DcydCDcydD and DcydCDpurD double mutants) of RB51 with the aim of increasing the safety of the possible use of these mutants as vaccine candidates. The RB51DcydC, RB51DcydD, RB51DpurD, RB51DcydCDcydD and RB51DcydCDpurD mutants exhibited significant attenuation of virulence when assayed in murine macrophages in vitro or in BALB/c mice. A single intraperitoneal immunization with RB51DcydC, RB51DcydD, RB51DcydCDcydD or RB51DcydCDpurD mutants was rapidly cleared from mice within 3 weeks, whereas the RB51DpurD mutant and RB51 were detectable in spleens until 4 and 7 weeks, respectively. Vaccination with a single dose of RB51 mutants induced lower protective immunity in mice than did parental RB51. However, a booster dose of these mutants provided significant levels of protection in mice against challenge with either the virulent homologous B. abortus strain 2308 or the heterologous Brucella canis strain 26. In addition, these mutants were found to induce a mixed but T-helper-1-biased humoral and cellular immune response in immunized mice. These data suggest that immunization with a booster dose of attenuated RB51 mutants provides an attractive strategy to protect against either bovine or canine brucellosis.

show abstract

“…Esses programas geralmente não fazem distinção entre as espécies bovina e bubalina, adotando estratégias comuns para ambas. Basicamente, esses programas apoiam-se em vacinação em massa de bezerras com a estirpe B19 ou RB51 e na certificação de rebanhos livres (OMS, 1986;SCHURIG et al, 2002).…”

Section: B Cetaceae (Isolados De Cetáceos)unclassified

Estudo comparativo de diferentes técnicas sorológicas para diagnóstico de infecções por Brucella abortus em búfalos (Bubalus bubalis)

Silva¹

View full text Add to dashboard Cite

Brucellosis vaccines: past, present and future

Cited by 346 publications

References 73 publications

From the discovery of the Malta fever?s agent to the discovery of a marine mammal reservoir, brucellosis has continuously been a re-emerging zoonosis

From the discovery of the Malta fever?s agent to the discovery of a marine mammal reservoir, brucellosis has continuously been a re-emerging zoonosis

Booster vaccination with safe, modified, live-attenuated mutants of Brucella abortus strain RB51 vaccine confers protective immunity against virulent strains of B. abortus and Brucella canis in BALB/c mice

Estudo comparativo de diferentes técnicas sorológicas para diagnóstico de infecções por Brucella abortus em búfalos (Bubalus bubalis)

Contact Info

Product

Resources

About